Expression of Survivin, Estrogen and Progesterone Receptor in Focal Tissues Before and After Treatment by High Intensity Focused Ultrasound for Nonneoplasia Epithelial Disorders of Skin and Mucosa of Vulva

doi:10.3877/cma.j.issn.1673-5250.2013.05.004

Objective

To investigate the expression levels and significance of estrogen receptor(ER), progesterone receptor (PR) and survivin in the focal tissues of non-neoplasia epithelial disorders of skin and mucosa of vulva(NEDV) before treatment and after 6 months of treatment by high intensity focused ultrasound(HIFU).

Methods

From January 2009 to September 2011, a total of 86 cases with NEDV, in an average age of (43.0±14.5) years old (15 to 75 years old), confirmed by biopsy pathology before treatment by HIFU, and 30 patients were randomly obtained the normal tissues nearby the focuses for control. According to histological classification of NEDV, 86 patients with NEDV were divided into three pathological types.Types of squamous hyperplasia(SHV)were 43 cases, lichen sclerosus(LSV)were 29 cases, and lichen sclerosus combined with squamous hyperplasia(LSCSH)were 14 cases.Immunohistochemical analysis for survivin, ER and PR expression were carried out on the tissue samples collected before treatment and after 6 months of treatment by HIFU. The methods of Vulvar Pruritus Score, Vulvar Leucoplakia Area Calculation and Vulvar Skin Elasticity were designed for objective evaluation of curative effect. Informed consent was obtained from all participants.

Results

After 6 months of treatment by HIFU, ① the curative rate of relieving-pruritus was 100%, and the average areas of vulvar leucoplakia of 86 patients with NEDV decreased from (11.21±7.50) cm² to (6.60±3.17) cm², and there were statistically more effective for Vulvar Pruritus Score and Vulvar Leucoplakia Area Calculation than those before treatment by HIFU(P<0.01). ②Expression levels of survivin, ER, and PR before treatment and after 6 months of treatment by HIFU, there had no statistical difference among the three pathological types: SHV, LSV and LSCSH(P>0.05), respectively. Positive rates of ER and PR expression before treatment and after 6 months of treatment by HIFU in normal vulvar tissues were much higher than those of focus tissues(P<0.05), but the survivin were much lower(P<0.05). ③Positive rates of ER and PR expression after 6 months of treatment by HIFU in focal tissues became much higher, as well as the surviving much lower than those before treatment by HIFU(P<0.05).

Conclusions

Expression levels increasing of survivin and decreasing of ER and PR could be the essential factors of pathogenesis for NEDV. Expression levels of survivin, ER and PR may play an important role in indicate the curative effect.

Key words: high intensity focused ultrasound, non-neoplasia epithelial disorders of skin and mucosa of vulva, pathogenesis, curative effect, estrogen/progesterone receptor, survivin

表1 研究组治疗前与治疗6个月时外阴瘙痒评分比较(分，±s)

Table 1 Comparison of vulvar pruritus scores before treatment and after 6 months of treatment in research group(score，±s)

组织学类型	n	评分		治愈率[n(%)]	t	P
组织学类型	n	治疗前	治疗后6个月时	治愈率[n(%)]	t	P
SHV	43	2.60±0.44	0.47±0.54	84.1(37/44)	2.857	<0.01
LSV	29	2.86±0.51	0.90±0.38	85.3(29/34)	3.184	<0.01
LSCSH	14	2.56±0.44	0.87±0.28	75.0 (6/8)	3.631	<0.01
合计	86	2.67±0.48	0.56±0.36	83.7(72/86)	2.731	<0.01

表1 研究组治疗前与治疗6个月时外阴瘙痒评分比较(分，±s)

Table 1 Comparison of vulvar pruritus scores before treatment and after 6 months of treatment in research group(score，±s)

组织学类型	n	评分		治愈率[n(%)]	t	P
组织学类型	n	治疗前	治疗后6个月时	治愈率[n(%)]	t	P
SHV	43	2.60±0.44	0.47±0.54	84.1(37/44)	2.857	<0.01
LSV	29	2.86±0.51	0.90±0.38	85.3(29/34)	3.184	<0.01
LSCSH	14	2.56±0.44	0.87±0.28	75.0 (6/8)	3.631	<0.01
合计	86	2.67±0.48	0.56±0.36	83.7(72/86)	2.731	<0.01

表2 研究组治疗前与治疗结束后6个月时外阴白色病变皮肤面积的比较(cm²，±s)

Table 2 Comparison of vulvar leucoplakia area calculation before treatment and after 6 months of treatment in research group(cm²，±s)

组织学类型	n	白色病变面积		治愈率[n(%)]	t	P
组织学类型	n	治疗前	治疗后6个月时	治愈率[n(%)]	t	P
SHV	43	12.90±6.60	3.67±1.61	77.3(34/44)	4.971	<0.01
LSV	29	10.66±3.77	4.87±1.45	58.8(20/34)	3.290	<0.01
LSCSH	14	10.99±5.34	3.87±0.28	62.5 (5/ 8)	3.321	<0.01
合计	86	11.21±7.50	6.60±3.17	68.6(59/86)	2.836	<0.01

表2 研究组治疗前与治疗结束后6个月时外阴白色病变皮肤面积的比较(cm²，±s)

Table 2 Comparison of vulvar leucoplakia area calculation before treatment and after 6 months of treatment in research group(cm²，±s)

组织学类型	n	白色病变面积		治愈率[n(%)]	t	P
组织学类型	n	治疗前	治疗后6个月时	治愈率[n(%)]	t	P
SHV	43	12.90±6.60	3.67±1.61	77.3(34/44)	4.971	<0.01
LSV	29	10.66±3.77	4.87±1.45	58.8(20/34)	3.290	<0.01
LSCSH	14	10.99±5.34	3.87±0.28	62.5 (5/ 8)	3.321	<0.01
合计	86	11.21±7.50	6.60±3.17	68.6(59/86)	2.836	<0.01

表3 研究组治疗前与治疗后6个月时外阴皮肤弹性评分比较(分，±s)

Table 3 Comparison of vulvar skin elasticity before treatment and after 6 months of treatment in research group(score，±s)

组织学类型	n	皮肤弹性评分		有效率[n(%)]	t	P
组织学类型	n	治疗前	治疗后6个月时	有效率[n(%)]	t	P
SHV	43	0.79±0.39	0.57±0.32	53.5(23/43)	1.933	>0.05
LSV	29	2.15±0.55	0.89±0.37	72.4(21/29)	3.291	<0.01
LSCSH	14	2.42±0.74	1.37±0.48	78.6(11/14)	3.291	<0.01
合计	86	2.07±0.57	0.84±0.30	64.0(55/86)	2.182	<0.05

表3 研究组治疗前与治疗后6个月时外阴皮肤弹性评分比较(分，±s)

Table 3 Comparison of vulvar skin elasticity before treatment and after 6 months of treatment in research group(score，±s)

组织学类型	n	皮肤弹性评分		有效率[n(%)]	t	P
组织学类型	n	治疗前	治疗后6个月时	有效率[n(%)]	t	P
SHV	43	0.79±0.39	0.57±0.32	53.5(23/43)	1.933	>0.05
LSV	29	2.15±0.55	0.89±0.37	72.4(21/29)	3.291	<0.01
LSCSH	14	2.42±0.74	1.37±0.48	78.6(11/14)	3.291	<0.01
合计	86	2.07±0.57	0.84±0.30	64.0(55/86)	2.182	<0.05

表4 研究组治疗前与治疗结束后6个月时3种类型外阴病变组织及其与对照组ER，PR及survivin表达水平比较 (%)

Table 4 Comparison of expression of ER, PR and survivin in focal tissues before treatment and after 6 months of treatment by HIFM among types of SHV, SHV, LSV, LSCSH in research group and in control group (%)

组别		n	ER (n)			阳性率	PR (n)			阳性率	survivin (n)			阳性率
组别		n	－	＋	≥2＋	阳性率	－	＋	≥2＋	阳性率	－	＋	≥2＋	阳性率
研究组SHV		43	?	?	?	?	?	?	?	?	?	?	?	?
?	治疗前	?	33	5	5	23.3	35	4	4	18.6	28	9	6	34.9
?	治疗后	?	23	9	11	46.5	26	8	9	39.5	40	2	1	7.0
?	χ²	?	?	?	?	5.119	?	?	?	4.586	?	?	?	10.118
?	P	?	?	?	?	0.024	?	?	?	0.033	?	?	?	0.001
研究组LSV		29	?	?	?	?	?	?	?	?	?	?	?	?
?	治疗前	?	24	2	3	17.2	25	2	2	29.4	20	5	4	31.0
?	治疗后	?	17	6	6	41.4	18	5	6	37.9	27	1	1	6.9
?	χ²	?	?	?	?	4.077	?	?	?	4.406	?	?	?	5.497
?	P	?	?	?	?	0.043	?	?	?	0.036	?	?	?	0.019
研究组LSCSH^a		14	?	?	?	?	?	?	?	?	?	?	?	?
?	治疗前	?	10	2	2	28.6	11	2	1	21.4	9	3	2	35.7
?	治疗后	?	6	4	4	57.1	7	4	3	50.0	13	1	0	7.1
?	P	?	?	?	?	0.252	?	?	?	0.236	?	?	?	0.169
研究组		86	?	?	?	?	?	?	?	?	?	?	?	?
?	治疗前	?	67	9	10	22.1	71	8	7	17.4	55	17	14	37.2
?	治疗后	?	46	19	21	46.5	41	27	18	52.3	80	4	2	7.0
?	χ²	?	?	?	?	11.377	?	?	?	23.036	?	?	?	21.522
?	P	?	?	?	?	0.001	?	?	?	0.000	?	?	?	0.000
研究组治疗前		86	67	9	10	22.1	71	8	7	17.4	55	17	14	37.2
?	对照组	30	14	7	9	53.3	19	5	6	36.7	30	0	0	0.0
?	χ²	?	?	?	?	10.303	?	?	?	4.727	?	?	?	?
?	P	?	?	?	?	0.001	?	?	?	0.03	?	?	?	?
研究组治疗后		86	46	19	21	46.5	41	27	18	52.3	80	4	2	7.0
?	对照组	30	14	7	9	53.3	19	5	6	36.7	30	0	0	0.0
?	χ²	?	?	?	?	0.414	?	?	?	2.184	?	?	?	?
?	P	?	?	?	?	0.520	?	?	?	0.924	?	?	?	?

表4 研究组治疗前与治疗结束后6个月时3种类型外阴病变组织及其与对照组ER，PR及survivin表达水平比较 (%)

组别		n	ER (n)			阳性率	PR (n)			阳性率	survivin (n)			阳性率
组别		n	－	＋	≥2＋	阳性率	－	＋	≥2＋	阳性率	－	＋	≥2＋	阳性率
研究组SHV		43	?	?	?	?	?	?	?	?	?	?	?	?
?	治疗前	?	33	5	5	23.3	35	4	4	18.6	28	9	6	34.9
?	治疗后	?	23	9	11	46.5	26	8	9	39.5	40	2	1	7.0
?	χ²	?	?	?	?	5.119	?	?	?	4.586	?	?	?	10.118
?	P	?	?	?	?	0.024	?	?	?	0.033	?	?	?	0.001
研究组LSV		29	?	?	?	?	?	?	?	?	?	?	?	?
?	治疗前	?	24	2	3	17.2	25	2	2	29.4	20	5	4	31.0
?	治疗后	?	17	6	6	41.4	18	5	6	37.9	27	1	1	6.9
?	χ²	?	?	?	?	4.077	?	?	?	4.406	?	?	?	5.497
?	P	?	?	?	?	0.043	?	?	?	0.036	?	?	?	0.019
研究组LSCSH^a		14	?	?	?	?	?	?	?	?	?	?	?	?
?	治疗前	?	10	2	2	28.6	11	2	1	21.4	9	3	2	35.7
?	治疗后	?	6	4	4	57.1	7	4	3	50.0	13	1	0	7.1
?	P	?	?	?	?	0.252	?	?	?	0.236	?	?	?	0.169
研究组		86	?	?	?	?	?	?	?	?	?	?	?	?
?	治疗前	?	67	9	10	22.1	71	8	7	17.4	55	17	14	37.2
?	治疗后	?	46	19	21	46.5	41	27	18	52.3	80	4	2	7.0
?	χ²	?	?	?	?	11.377	?	?	?	23.036	?	?	?	21.522
?	P	?	?	?	?	0.001	?	?	?	0.000	?	?	?	0.000
研究组治疗前		86	67	9	10	22.1	71	8	7	17.4	55	17	14	37.2
?	对照组	30	14	7	9	53.3	19	5	6	36.7	30	0	0	0.0
?	χ²	?	?	?	?	10.303	?	?	?	4.727	?	?	?	?
?	P	?	?	?	?	0.001	?	?	?	0.03	?	?	?	?
研究组治疗后		86	46	19	21	46.5	41	27	18	52.3	80	4	2	7.0
?	对照组	30	14	7	9	53.3	19	5	6	36.7	30	0	0	0.0
?	χ²	?	?	?	?	0.414	?	?	?	2.184	?	?	?	?
?	P	?	?	?	?	0.520	?	?	?	0.924	?	?	?	?

1	Xiong ZA. Nonneoplasia epithelial disorders of skin and mucosa of Vulva//Yue J. Obstetrics and gynecology. 7th ed[M]．Beijing：People's Medical Publishing House，2008，331-335.
2	Yin GP, He N. Curative effect of high intensity focusedultrasound for nonneoplasia epithelial disorders of skin and mucosa of vulva[J]．Prog Obstet Gynecol, 2007，17(8)：633-634.
3	Yin GP, Ti SM, Yang SJ，et al. Therapeutic methods and effects of high intensity focused ultrasound on the treatment of nonneoplasia epithelial disorders of skin and mucosa of vulva[J/CD]. Chin J Obstet Gynecol Pediatr：Electron Ed，2010，6(4)：265-269.
4	Yin GP, Li J, Zhu TY，et al. Expression of survivin, estrogen receptor and progesterone receptor of endometrium of patients with anovulatory dysfunctional uterine bleeding before and after radiofequency heat-coaglulation treantmen[J/CD]. Chin J Obstet Gynecol Pediatr: Electron Ed，2010，6(3)：175-181.
5	Garau JM, Di Paola GH. Estrogen and progesterone receptor assays on the vulvar epithelium[J]. J Peprod Med，1986, 31(10)：987-991.
6	Liu HM, Xie J, Li ZH. Progress of treatment for nonneoplasia epithelial disorders of skin and mucosa of vulva[J]．J Military Surg Southwest China, 2008，10(6)：20-23.
7	Jiao NX, Hu LN, Xiong ZA, et al. Clinical curative effect study in treatment of 900 patients with intraepithelial non-tumor-like lesion of vulvae with focused ultrasound[J]．Chin J Obstet Gynecol, 2007, 42(1)：7-8.
8	Liu YH, Lin SY, Guo SQ, et al. Theory and application of high intensity focused ultrasound[J]. Progr Modern Biomed，2008, 8(7)：1344-1345.
9	Nagai MA, Brentani MM. Gene expression profiles in breast cancer to identify estrogen receptor target genes[J]. Mini Rev Med Chem，2008, 8(5): 448-454.
10	Ogle TF. Progesterone-action in the decidual mesometrium of pregnancy[J]．Steroids, 2002, 67(1)：1-14.
11	Weikert S, Schrader M, Krause H, et al. The inhibitor of apoptosis (IAP) survivin is expressed in human testiculas qerm cell tumor and normal testes[J]. Cancer Lett, 2005, 223(2)：331-337.

[1]	Meiyi Chen, Yiyao Li, Mengyuan Zhang, Jie Xu, Ruofan Ma, Deng Li, Jing Gu. Application research of visual self-rating system for hip joint function evaluation[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(03): 320-328.
[2]	Qilong Zhang, Yi Liu, Huili Lu, Hui Luo, Chenglin Li, Jing Wang, Hui Wang. A single-center retrospective analysis of efficacy and safety of obinutuzumab for treating phospholipase A₂ receptor associated membranous nephropathy[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(05): 379-384.
[3]	Xiaowei Chang, Yu Cai, Zhiyong Zhao, Wei Zhang. Efficacy and safety analysis of high intensity focused ultrasound ablation combined with hepatic arterial chemoembolization in the treatment of primary hepatocellular carcinoma[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 56-59.
[4]	Hong Tang, Qi Zhou, Xiaoling Ouyang, Yongfeng Wang, Yu Hua, Xiaobai Hao, Linxia Li. The therapeutic effect of extraperitoneal tension-free uterine suspension in the treatment of pelvic organ prolapse[J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(03): 315-319.
[5]	Kongyuan Wei, Zheng Wu, Zheng Wang, Wei Li. A preliminary study on different reconstruction methods of distal pancreas after robotic central pancreatectomy[J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(05): 295-300.
[6]	Yufan Meng, Yongzheng Li, Zhiyao Fan, Hanxiang Zhan. Mechanism and research progress in intratumoral microbiota in the pathogenesis and progression of pancreatic cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 577-582.
[7]	Jing Zhao, Jiaxin Zhang, Yan Gao, Xisheng Xie. Progress of research on minimal change disease in its pathogenesis and treatment[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(04): 207-212.
[8]	Ding Sun, Bin Wang, Xiangmei Chen, Yizhi Chen. Progress in the study of heat stress nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(03): 170-176.
[9]	Hongyan Jia, Dan Wang, Ranran Zhang, Qian Ma, Yonghong Jiao. Genetic analysis on the pathogenesis of Möbius syndrome based on whole exome sequencing[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2024, 14(03): 146-154.
[10]	Shuang Ren, Yiying Liu, Yang Li. Clinical effect of rebamipide combined with esomeprazole in the treatment of erosive gastritis[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(03): 249-252.
[11]	Yanan An, Duanran Wang, Tiantian Guo, Xirun Wu. Research progress of Helicobacter pylori negative gastric mucosa-associated lymphoid tissue lymphoma[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(03): 268-274.
[12]	Qi Liu, Shoukai Wang, Shuai Wang, Yuqing Su, Zhuang Ma, Haijun Chen, Pilei Si. Advances in research of intratumoral microbiome in breast cancer[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(09): 841-845.
[13]	Yue Yang, Xiaoye Tuo, Zihao Cui, Simin Ouyang, Haiyang Lin, Jingyu Hu, Yin Hu, Tao Li, Jingfeng Zhao, Daifeng Hao, Guang Feng. Curative effect of modified reading-man flap on sacrococcygeal pressure sore[J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(08): 751-755.
[14]	Ruonan Li, Jin Song, Yuzhong Wang. Progress on the pathogenesis and diagnosis and treatment of postherpetic neuralgia[J]. Chinese Journal of Diagnostics(Electronic Edition), 2024, 12(03): 199-205.
[15]	Yue Yu, Yuan Wang, Muhui Sang, Qin Shi. Analysis of vertigo pathogenesis syndrome element distribution using a vertigo syndrome differentiation scale[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2024, 18(05): 454-458.

Viewed

Full text

Abstract

Please choose a citation manager

Content to export